FR2804959B1 - Utilisation de derives de paullones pour la fabrication de medicaments - Google Patents

Utilisation de derives de paullones pour la fabrication de medicaments

Info

Publication number
FR2804959B1
FR2804959B1 FR0001862A FR0001862A FR2804959B1 FR 2804959 B1 FR2804959 B1 FR 2804959B1 FR 0001862 A FR0001862 A FR 0001862A FR 0001862 A FR0001862 A FR 0001862A FR 2804959 B1 FR2804959 B1 FR 2804959B1
Authority
FR
France
Prior art keywords
paullon
medicaments
derivatives
manufacture
paullon derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0001862A
Other languages
English (en)
Other versions
FR2804959A1 (fr
Inventor
Laurent Meijer
Conrad Kunick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0001862A priority Critical patent/FR2804959B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to CA002397560A priority patent/CA2397560A1/fr
Priority to AU2001235691A priority patent/AU2001235691A1/en
Priority to US10/203,977 priority patent/US7232814B2/en
Priority to PCT/FR2001/000455 priority patent/WO2001060374A1/fr
Priority to JP2001559470A priority patent/JP2003522793A/ja
Priority to EP01907815A priority patent/EP1255551A1/fr
Publication of FR2804959A1 publication Critical patent/FR2804959A1/fr
Application granted granted Critical
Publication of FR2804959B1 publication Critical patent/FR2804959B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
FR0001862A 2000-02-15 2000-02-15 Utilisation de derives de paullones pour la fabrication de medicaments Expired - Fee Related FR2804959B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0001862A FR2804959B1 (fr) 2000-02-15 2000-02-15 Utilisation de derives de paullones pour la fabrication de medicaments
AU2001235691A AU2001235691A1 (en) 2000-02-15 2001-02-15 Use of paullone derivatives for making medicines
US10/203,977 US7232814B2 (en) 2000-02-15 2001-02-15 Use of paullone derivatives for making medicines
PCT/FR2001/000455 WO2001060374A1 (fr) 2000-02-15 2001-02-15 Utilisation de derives de paullones pour la fabrication de medicaments
CA002397560A CA2397560A1 (fr) 2000-02-15 2001-02-15 Utilisation de derives de paullones pour la fabrication de medicaments
JP2001559470A JP2003522793A (ja) 2000-02-15 2001-02-15 製薬におけるパウロン誘導体の使用
EP01907815A EP1255551A1 (fr) 2000-02-15 2001-02-15 Utilisation de derives de paullones pour la fabrication de medicaments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0001862A FR2804959B1 (fr) 2000-02-15 2000-02-15 Utilisation de derives de paullones pour la fabrication de medicaments

Publications (2)

Publication Number Publication Date
FR2804959A1 FR2804959A1 (fr) 2001-08-17
FR2804959B1 true FR2804959B1 (fr) 2006-04-28

Family

ID=8847019

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0001862A Expired - Fee Related FR2804959B1 (fr) 2000-02-15 2000-02-15 Utilisation de derives de paullones pour la fabrication de medicaments

Country Status (7)

Country Link
US (1) US7232814B2 (fr)
EP (1) EP1255551A1 (fr)
JP (1) JP2003522793A (fr)
AU (1) AU2001235691A1 (fr)
CA (1) CA2397560A1 (fr)
FR (1) FR2804959B1 (fr)
WO (1) WO2001060374A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
WO2002030410A2 (fr) * 2000-10-10 2002-04-18 Board Of Regents, The University Of Texas System Suppression de l'activite de kinase cycline-dependante pour la prevention et le traitement des infections
CN1247586C (zh) 2001-09-21 2006-03-29 赛诺菲安万特 治疗神经退化性疾病的取代的2－嘧啶基－6,7,8,9－四氢嘧啶并[1,2－a]嘧啶－4－酮及7－嘧啶基－2,3－二氢咪唑并[1,2－a]嘧啶－5(1h)酮衍生物
EP1295884A1 (fr) * 2001-09-21 2003-03-26 Sanofi-Synthelabo Dérivés de 2-Pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-Pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one
JP4527404B2 (ja) * 2002-04-04 2010-08-18 エンゾン，インコーポレーテッド インドールのポリマー性アシル誘導体
EP1925306A3 (fr) * 2002-04-30 2008-09-17 Alcon, Inc. Agents regulant, inhibant ou modulant l'activite et/ou l'expression du facteur de croissance du tissu conjonctif (ctgf) pour reduire la pression intraoculaire
WO2003092584A2 (fr) 2002-04-30 2003-11-13 Alcon, Inc. Agents regulant, inhibant ou modulant l'activite et/ou l'expression du facteur de croissance du tissu conjonctif (ctgf) utilises comme moyen unique pour reduire la pression intraoculaire et traiter les retinopathies glaucomateuses/neuropathies optiques
DE10260618B4 (de) * 2002-12-23 2005-06-09 Faustus Forschungs Cie. Translational Cancer Research Gmbh Tumorhemmende annellierte Azepinonderivate
EP1615658A1 (fr) * 2003-03-25 2006-01-18 The Board Of Trustees Of The University Of Illinois Procede d'inhibition de proliferation de cellules tumorales
PL1748691T3 (pl) * 2004-05-12 2011-04-29 Bayer Cropscience Ag Sposób regulacji wzrostu roślin
CN1980681A (zh) * 2004-07-09 2007-06-13 新加坡科技研究局 GSK－3β的调节及治疗增殖性病变的方法
WO2006024947A2 (fr) * 2004-09-02 2006-03-09 Neuro Therapeutics Ab Methodes et materiaux concernant une production accrue de neurones a dopamine
AU2005294575B2 (en) * 2004-10-04 2011-11-24 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
FR2876584B1 (fr) * 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de la kenpaullone pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
US20080207594A1 (en) * 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
WO2006117221A1 (fr) * 2005-05-04 2006-11-09 Develogen Aktiengesellschaft Utilisation d'azapaullones pour la prevention et le traitement de troubles auto-immunes du pancreas
MX2008000461A (es) 2005-07-12 2008-03-10 Abbott Gmbh & Co Kg Compuestos de piridazina como inhibidores de la glucogeno sintasa cinasa 3.
EP1757607A1 (fr) 2005-08-24 2007-02-28 Molisa GmbH Benzo¬2,3|azepino¬4,5-b|indol-6-ones N5-substitués pour le traitement des maladies tropiques
EP2258358A3 (fr) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
EP1928437A2 (fr) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenese par modulation du recepteur muscarinique
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
FR2899107B1 (fr) * 2006-03-30 2008-06-13 Neurokin Entpr Unipersonnelle Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2007134077A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse induite par le récepteur 5ht
EP2068872A1 (fr) 2006-09-08 2009-06-17 Braincells, Inc. Combinaisons contenant un dérivé de 4-acylaminopyridine
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8029980B2 (en) 2006-09-29 2011-10-04 The Board Of Trustees Of The University Of Illinois Identification and use of agents that modulate oncogenic transcription agent activity
WO2008097861A2 (fr) * 2007-02-02 2008-08-14 Braincells, Inc. Modulation d'une neurogénèse avec des biguanides et des agents gsk3-ss
WO2009010298A2 (fr) * 2007-07-18 2009-01-22 Technische Universität Carolo-Wilhelmina Zu Braunschweig Dérivés de paullone et leurs utilisation
AU2008297011B2 (en) 2007-08-31 2014-06-12 Whitehead Institute For Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
WO2010048273A2 (fr) * 2008-10-21 2010-04-29 President And Fellows Of Harvard College Procédés et composés pour le traitement de troubles neurodégénératifs
US7998952B2 (en) 2008-12-05 2011-08-16 Millennium Pharmaceuticals, Inc. Thiolactams and uses thereof
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
US20110088107A1 (en) * 2009-04-24 2011-04-14 Yaqub Hanna Compositions and methods for deriving or culturing pluripotent cells
US9572815B2 (en) 2013-03-15 2017-02-21 St. Jude Children's Research Hospital Methods and compositions of p27KIP1 transcriptional modulators
WO2016201581A1 (fr) 2015-06-18 2016-12-22 The Hospital For Sick Children Procédé de traitement de médulloblastome
EP3786164B1 (fr) 2015-06-18 2024-08-14 Ting Therapeutics LLC Procédés et compositions pour la prévention et le traitement de la perte auditive

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
WO1999065910A1 (fr) * 1998-06-16 1999-12-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Inhibiteurs de kinases dependantes de la cycline sous forme d'azepinone fusionnee

Also Published As

Publication number Publication date
FR2804959A1 (fr) 2001-08-17
AU2001235691A1 (en) 2001-08-27
WO2001060374A1 (fr) 2001-08-23
US20030181439A1 (en) 2003-09-25
CA2397560A1 (fr) 2001-08-23
EP1255551A1 (fr) 2002-11-13
JP2003522793A (ja) 2003-07-29
US7232814B2 (en) 2007-06-19

Similar Documents

Publication Publication Date Title
FR2804959B1 (fr) Utilisation de derives de paullones pour la fabrication de medicaments
NO2020040I1 (no) eltrombopag olamine - Forlenget SPC
EE200300497A (et) Pürasoolderivaadid HIV raviks
PT1175408E (pt) Derivados sulfonamida
ATE309998T1 (de) Pharmazeutisch wirksamer sulfonamid derivaten
DK1250138T3 (da) Fulvestrantformulering
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
NO20014379D0 (no) Anvendelse av Xenon for behandling av Neurointoksikasjoner
EE05020B1 (et) Glburiidi ravimkoostis
NO20031229D0 (no) Fremgangsmåte for fremstilling av börstevarer
ATE459598T1 (de) Sulfonamidderivate
EE200300294A (et) Sulfoonamiid-asendatud imidasotriasinoonide valmistamismeetod
DE60212604D1 (de) Tamponpackung
NO20030515D0 (no) Fremgangsmåte for fremstilling av dinapsolin
DE10083002T1 (de) Seifenverpackung
NO20024887L (no) FremgangsmÕte for fremstilling av benzokondenserte heterosykliske forbindelser
EE200300466A (et) Püridoindolooni derivaatide kasutamine ravimite valmistamiseks
FR2821270B1 (fr) Utilisation de nicotine libre pour la fabrication d'une composition anti-cellulitique
NO20023702L (no) Fremgangsmåte for fremstilling av 5-arylnikotinaldehyder
FR2791245B3 (fr) Baignoire pour bebes
DK1183236T3 (da) Cinnamoylaminoalkylsubstituerede benzensulfonamidderivater
EP1157700A4 (fr) Agent anti-vih
FR2791246B3 (fr) Baignoire pour bebes
NO20025385L (no) Fremgangsmate for fremstilling av sulfonylbenzoylguanidiniumsalter
NO20005856D0 (no) Anvendelse av 1,1-diokso-perhydro-1,2,4-tiadiaziner

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20111102